RecruitingNCT02650622

Genetic and Metabolic Disease in Children

Genetic Regulators of Metabolism and Development in Children


Sponsor

University of Texas Southwestern Medical Center

Enrollment

1,550 participants

Start Date

Jun 1, 2015

Study Type

OBSERVATIONAL

Conditions

Summary

This is a prospective, non-randomized, non-blinded observational study. The overarching goal is to discover new disease-associated genes in children, while establishing a specific focus on disorders where molecular characterization is most likely to lead to novel therapies. This study will merge detailed phenotypic characterization of patients presenting to the Pediatric Genetics and Metabolism Division in the Department of Pediatrics/Children's Medical Center at Dallas and collaborating clinics with Next-Generation sequencing techniques to identify disease-producing mutations. The primary objective of the study is to identify novel pathogenic mutations in children with rare Mendelian disorders. A secondary objective of the study is to establish normative ranges of a large number of metabolites from healthy newborns and older children.


Eligibility

Min Age: 1 Day

Inclusion Criteria11

  • Subjects aged 1-2 days
  • Subjects with gestational age 37-42 weeks
  • Subjects with stable clinical status (admitted to normal newborn nursery)
  • Subjects aged 0-18 years
  • Subjects (no age limit) with ANY phenotype as below:
  • Confirmed metabolic or genetic diseases
  • Suspected metabolic or genetic diseases
  • Episodic metabolic decompensation (e.g. hypoglycemia, hyperammonemia, metabolic acidosis)
  • Developmental regression
  • Major congenital malformation
  • Other unexplained symptoms of potential genetic origin

Exclusion Criteria8

  • Subjects with gestational age <37 weeks or >42 weeks
  • Subjects with overt signs of metabolic dysfunction, distress or genetic diseases including hypoglycemia, hyperglycemia, sepsis/shock, hypoxemia, or major congenital malformation
  • Subjects with mothers whose pregnancies were complicated by gestational diabetes, gestational hyperglycemia, gestational hypertension, preeclampsia, or any other major disorders.
  • Subjects with confirmed metabolic or genetic diseases
  • Subjects with suspected metabolic or genetic diseases
  • Subjects with episodic metabolic decompensation (e.g. hypoglycemia, hyperammonemia, metabolic acidosis)
  • Subjects with developmental regression
  • Subjects with major congenital malformation

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURESkin Biopsy

Skin biopsy will only be performed on the proband children in the cohort 3. A small piece of skin (less than 1/8'') will be removed using a local anesthetic cream and a punch, which will then be used for culture of skin cells and other laboratory tests on metabolic function.


Locations(1)

Children's Medical Center at Dallas

Dallas, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02650622


Related Trials